| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/14767058.2011.591461 |
| P8608 | Fatcat ID | release_cr6hgs4uvbeolg6xfwfulzuza4 |
| P932 | PMC publication ID | 3401571 |
| P698 | PubMed publication ID | 21867402 |
| P5875 | ResearchGate publication ID | 51595644 |
| P50 | author | Tinnakorn Chaiworapongsa | Q69022472 |
| Juan Pedro Kusanovic | Q88155059 | ||
| Lami Yeo | Q88230658 | ||
| Chong Jai Kim | Q89767788 | ||
| Sonia S Hassan | Q96619726 | ||
| Roberto Romero | Q42734915 | ||
| P2093 | author name string | Giovanna Ogge | |
| Eleazar Soto | |||
| Youssef Hussein | |||
| P2860 | cites work | Tissue factor and its natural inhibitor in pre-eclampsia and SGA | Q24323351 |
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia | Q28244090 | ||
| Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression | Q28573546 | ||
| WHO analysis of causes of maternal death: a systematic review | Q29615135 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies | Q30990384 | ||
| Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion | Q33316902 | ||
| Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry | Q33329370 | ||
| Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancy-induced hypertension | Q33436692 | ||
| The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. | Q33755648 | ||
| Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia | Q33821579 | ||
| Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications | Q33976312 | ||
| ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. | Q33990220 | ||
| Development of the placental villous tree and its consequences for fetal growth | Q34032277 | ||
| Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations | Q34151967 | ||
| Retinol binding protein 4--a novel association with early-onset preeclampsia | Q34234671 | ||
| Expression of bone morphogenetic protein 2 in normal spontaneous labor at term, preterm labor, and preterm premature rupture of membranes. | Q34313694 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? | Q34835710 | ||
| Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae | Q34975562 | ||
| Role of placenta in preeclampsia. | Q35065105 | ||
| Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia. | Q51731766 | ||
| Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. | Q51794305 | ||
| Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. | Q51914188 | ||
| Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. | Q52192148 | ||
| Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. | Q52237839 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Soluble endoglin as a second-trimester marker for preeclampsia. | Q53535438 | ||
| Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. | Q53538854 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. | Q53614458 | ||
| The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. | Q54599986 | ||
| Toll-like receptor 4: a potential link between "danger signals," the innate immune system, and preeclampsia? | Q54644102 | ||
| First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia | Q56619507 | ||
| Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction | Q57316937 | ||
| Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction | Q57316953 | ||
| Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia | Q58377198 | ||
| Maternal anti-protein Z antibodies in pregnancies complicated by pre-eclampsia, SGA and fetal death | Q58417749 | ||
| Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction | Q58623928 | ||
| Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia | Q58778301 | ||
| Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia | Q58778344 | ||
| Placental diagnostic criteria and clinical correlation – a workshop report | Q59662967 | ||
| Trophoblast deportation and the maternal inflammatory response in pre-eclampsia | Q35190881 | ||
| Maternal serum adiponectin multimers in preeclampsia | Q35194054 | ||
| Subclassification of preeclampsia | Q35196220 | ||
| Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia | Q35542826 | ||
| The "Great Obstetrical Syndromes" are associated with disorders of deep placentation | Q36015615 | ||
| A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia | Q36189562 | ||
| A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia | Q36221448 | ||
| Recent advances in understanding of preeclampsia. | Q36255904 | ||
| The complications of hypertension in pregnancy. | Q36265559 | ||
| Preeclampsia: recent insights | Q36288757 | ||
| Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma | Q36317153 | ||
| Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products | Q36351625 | ||
| Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor | Q36360704 | ||
| Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia | Q36618406 | ||
| Emerging concepts in preeclampsia investigation | Q36664115 | ||
| Preeclampsia is associated with low concentrations of protein Z. | Q36670687 | ||
| Taking tissue samples from the placenta: an illustration of principles and strategies | Q36894150 | ||
| Adiponectin in severe preeclampsia. | Q36946738 | ||
| The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro | Q36975531 | ||
| A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma | Q36984261 | ||
| Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. | Q37039719 | ||
| Hypertensive disorders of pregnancy: the United States perspective | Q37128585 | ||
| The two stage model of preeclampsia: variations on the theme | Q37187589 | ||
| Severe preeclampsia is characterized by increased placental expression of galectin-1 | Q37416956 | ||
| A role for mannose-binding lectin, a component of the innate immune system in pre-eclampsia | Q37416963 | ||
| Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. | Q37416997 | ||
| First-trimester maternal serum PP13 in the risk assessment for preeclampsia. | Q37444801 | ||
| Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats | Q37449704 | ||
| Preeclampsia: the role of angiogenic factors in its pathogenesis | Q37512886 | ||
| The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia | Q37607698 | ||
| Immunology of pre-eclampsia | Q37717752 | ||
| Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia | Q37777854 | ||
| Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. | Q37844756 | ||
| Angiogenesis gene expression in mouse uterus during the common pathway of parturition. | Q38513835 | ||
| The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation | Q61845344 | ||
| Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia | Q61845360 | ||
| Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia | Q61845530 | ||
| Clinical significance of liver dysfunction in pregnancy-induced hypertension | Q61845930 | ||
| Early and Late Preeclampsia | Q61853974 | ||
| Preeclampsia and fetal growth | Q61911566 | ||
| Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women | Q62487968 | ||
| A United States national reference for fetal growth | Q70895060 | ||
| Increased release of tumor necrosis factor-alpha and interleukin-6 in women with the syndrome of hemolysis, elevated liver enzymes, and low platelet count | Q71754126 | ||
| Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree | Q71955316 | ||
| Treatment of endothelial cells with serum from women with preeclampsia: effect on neutrophil adhesion | Q73112926 | ||
| Apoptosis cascade progresses during turnover of human trophoblast: analysis of villous cytotrophoblast and syncytial fragments in vitro | Q73314016 | ||
| Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group | Q73937666 | ||
| Activation of leukocytes during the uteroplacental passage in preeclampsia | Q77513220 | ||
| Preeclampsia is associated with reduced serum levels of placenta growth factor | Q77690843 | ||
| Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia | Q78400398 | ||
| Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathologic conditions | Q78582024 | ||
| Circulating angiogenic factors and abnormal uterine artery Doppler velocimetry in the second trimester | Q79300722 | ||
| Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion | Q79685499 | ||
| Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia | Q79714247 | ||
| Is pre-eclampsia more than one disease? | Q79752866 | ||
| Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia | Q79823183 | ||
| Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia | Q79903356 | ||
| Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia | Q80219809 | ||
| Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies | Q80379702 | ||
| Placental growth factor (PlGF) is a surrogate marker in preeclamptic hypertension | Q80754551 | ||
| Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia | Q80774704 | ||
| Angiogenic factors for the prediction of preeclampsia in high-risk women | Q81160614 | ||
| Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression | Q81411178 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation | Q81429334 | ||
| Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? | Q81931106 | ||
| Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis | Q82470256 | ||
| Activation of the complement system in normal pregnancy and preeclampsia | Q83021096 | ||
| Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension | Q83799951 | ||
| Are early and late preeclampsia distinct subclasses of the disease--what does the placenta reveal? | Q84719522 | ||
| Toxemia: new concepts in an old disease | Q39559348 | ||
| Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia | Q40184951 | ||
| Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction | Q40238276 | ||
| Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns | Q40524863 | ||
| Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia | Q40530224 | ||
| Preeclampsia: an excessive maternal inflammatory response to pregnancy | Q40824430 | ||
| Preeclampsia: an endothelial cell disorder | Q41281924 | ||
| Placental cytokines and the pathogenesis of preeclampsia | Q41452017 | ||
| Histomorphometry of the human placenta in maternal preeclampsia | Q41497896 | ||
| Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia | Q42511665 | ||
| Modified Bishop's score and induction of labor in patients with a previous cesarean delivery | Q43519943 | ||
| Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005. | Q43621863 | ||
| Hypertensive disorders and severe obstetric morbidity in the United States | Q43893631 | ||
| Placental bed spiral arteries in the hypertensive disorders of pregnancy | Q44053736 | ||
| Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women | Q44112633 | ||
| Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation | Q44302005 | ||
| Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity | Q44624181 | ||
| NAD(P)H oxidase associated superoxide production in human placenta from normotensive and pre-eclamptic women | Q44806758 | ||
| Maternal uterine vascular lesions in the hypertensive complications of pregnancy | Q45101307 | ||
| Allelic variations in angiogenic pathway genes are associated with preeclampsia. | Q46046664 | ||
| Pre-eclampsia in the first pregnancy and subsequent risk of stillbirth in black and white gravidas | Q46262039 | ||
| Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks | Q46321423 | ||
| Late Onset Preeclampsia is not an Innocuous Condition | Q46330403 | ||
| Rise in maternal mortality in the Netherlands | Q46332504 | ||
| Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. | Q46339760 | ||
| Epidemiology of pre-eclampsia and eclampsia at the KK Women's and Children's Hospital, Singapore | Q46342633 | ||
| Pregnancy-related mortality from preeclampsia and eclampsia | Q46353535 | ||
| Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group | Q46355603 | ||
| Endothelial cell activation as a pathogenetic factor in preeclampsia | Q46585360 | ||
| Low urinary placental growth factor is a marker of pre-eclampsia | Q46881114 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| The frequency and severity of placental findings in women with preeclampsia are gestational age dependent | Q47414750 | ||
| Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women | Q47770771 | ||
| Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia | Q47915288 | ||
| Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta | Q48331835 | ||
| Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 | ||
| Adriana and Luisa Castellucci Award Lecture 1997. Placental pathology in obstetrics: adaptation or failure of the villous tree? | Q48381213 | ||
| Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. | Q50734891 | ||
| Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. | Q50775910 | ||
| Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. | Q50779076 | ||
| P433 | issue | 5 | |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| pre-eclampsia | Q61335 | ||
| P304 | page(s) | 498-507 | |
| P577 | publication date | 2011-08-25 | |
| P1433 | published in | Journal of Maternal-Fetal and Neonatal Medicine | Q6295498 |
| P1476 | title | Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion | |
| P478 | volume | 25 |
| Q40544172 | Absolute first trimester cell-free DNA levels and their associations with adverse pregnancy outcomes |
| Q50483761 | Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-for- gestational-age fetuses. |
| Q39117000 | Anti-angiogenesis and Preeclampsia in 2016. |
| Q36357099 | Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary? |
| Q36866567 | Decidual Cox2 inhibition improves fetal and maternal outcomes in a preeclampsia-like mouse model |
| Q51802500 | Do the physiological aging of the placenta and the changes in angiogenesis marker sFlt-1 and PlGF concentrations predispose patients to late-onset preeclampsia? |
| Q61844895 | ELABELA plasma concentrations are increased in women with late-onset preeclampsia |
| Q49916807 | Effects of excess thromboxane A2 on placental development and nutrient transporters in a Mus musculus model of fetal growth restriction. |
| Q37612429 | Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death |
| Q42099246 | FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia |
| Q40402667 | Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta. |
| Q50017347 | Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis |
| Q35204444 | Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice |
| Q36993201 | Increased Risk of Intracranial Hemorrhage in Patients With Pregnancy-Induced Hypertension: A Nationwide Population-Based Retrospective Cohort Study |
| Q37605722 | Increased risk of systemic lupus erythematosus in pregnancy-induced hypertension: A nationwide population-based retrospective cohort study |
| Q58795465 | Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia |
| Q49243157 | Is an episode of suspected preterm labor that subsequently leads to a term delivery benign? |
| Q100761882 | Late first trimester circulating microparticle proteins predict the risk of preeclampsia < 35 weeks and suggest phenotypic differences among affected cases |
| Q56523646 | Lipoxin A4 Is Increased in the Plasma of Preeclamptic Women |
| Q41033848 | Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study |
| Q55004295 | Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. |
| Q40367971 | Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study |
| Q39376655 | Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity |
| Q34670424 | Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol |
| Q44314054 | Perfusion with magnesium sulfate increases sFlt-1 secretion only in the fetal side of placenta of women with preeclampsia |
| Q37337545 | Placental disease and the maternal syndrome of preeclampsia: missing links? |
| Q38075008 | Placental growth factor (PlGF): a key to optimizing fetal growth |
| Q36965288 | Placental growth factor: as an early second trimester predictive marker for preeclampsia in normal and high-risk pregnancies in a Turkish population |
| Q35558666 | Placental lesions associated with acute atherosis |
| Q34119026 | Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study |
| Q92903848 | Plasma concentrations of soluble endoglin in the maternal circulation are associated with maternal vascular malperfusion lesions in the placenta of women with preeclampsia |
| Q84564963 | Plasma level of hydroxysteroid (17-β) dehydrogenase 1 in the second trimester is an independent risk factor for predicting preeclampsia after adjusting for the effects of mean blood pressure, bilateral notching and plasma level of soluble fms-like t |
| Q33625295 | Potential role of A2B adenosine receptors on proliferation/migration of fetal endothelium derived from preeclamptic pregnancies. |
| Q36455584 | Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). |
| Q33416340 | Pre-eclampsia part 1: current understanding of its pathophysiology |
| Q55517979 | Prediction of pre-eclampsia and its subtypes in high-risk cohort: hyperglycosylated human chorionic gonadotropin in multivariate models. |
| Q33432708 | Preeclampsia, of mice and women |
| Q34200215 | Prenatal diagnosis of a placental infarction hematoma associated with fetal growth restriction, preeclampsia and fetal death: clinicopathological correlation |
| Q34428934 | Role of decidual natural killer cells, interleukin-15, and interferon-γ in placental development and preeclampsia |
| Q37620584 | Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy |
| Q30276543 | Stillbirth, hypertensive disorders of pregnancy, and placental pathology |
| Q36104833 | Systematic Review of Micro-RNA Expression in Pre-Eclampsia Identifies a Number of Common Pathways Associated with the Disease |
| Q61844931 | The frequency and type of placental histologic lesions in term pregnancies with normal outcome |
| Q37317538 | The impact of resilience on psychological outcomes in women after preeclampsia: an observational cohort study |
| Q92515855 | The prediction of early preeclampsia: Results from a longitudinal proteomics study |
| Q47645647 | The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio). |
| Q38664824 | The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study |
| Q50102668 | The profiles of soluble adhesion molecules in the "great obstetrical syndromes". |
| Q49312791 | The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia |
| Q47187556 | Uterine artery Doppler, birth weight and timing of onset of pre-eclampsia: providing insights into the dual etiology of late-onset pre-eclampsia |
Search more.